Search Result
Results for "
CPT
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-16560
-
Campathecin; (S)-(+)-Camptothecin; CPT
|
Topoisomerase
ADC Cytotoxin
MicroRNA
Influenza Virus
Apoptosis
Fungal
Antibiotic
|
Infection
Cancer
|
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .
|
-
-
- HY-111469
-
|
Phosphatase
|
Metabolic Disease
|
CPT-157633, a difluoro-phosphonomethyl phenylalanine derivative, and is a PTP1B inhibitor. CPT-157633 prevents binge drinking-induced glucose intolerance .
|
-
-
- HY-145290
-
|
Topoisomerase
Apoptosis
|
Cancer
|
CPT-Se3, a selenoproagent of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT–Se3 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se3 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.19-4.7 μM) .
|
-
-
- HY-145291
-
|
Topoisomerase
Apoptosis
|
Cancer
|
CPT-Se4, a selenoproagent of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT-Se4 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se4 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.54-6.4 μM) .
|
-
-
- HY-108433
-
Carnitine palmitoyltransferase 2
|
Apoptosis
MDM-2/p53
|
Metabolic Disease
Cancer
|
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .
|
-
-
- HY-RS03125
-
|
Small Interfering RNA (siRNA)
|
Others
|
CPT2 Human Pre-designed siRNA Set A contains three designed siRNAs for CPT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
CPT2 Human Pre-designed siRNA Set A
CPT2 Human Pre-designed siRNA Set A
-
- HY-RS03122
-
|
Small Interfering RNA (siRNA)
|
Others
|
CPT1A Human Pre-designed siRNA Set A contains three designed siRNAs for CPT1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
CPT1A Human Pre-designed siRNA Set A
CPT1A Human Pre-designed siRNA Set A
-
- HY-RS03123
-
|
Small Interfering RNA (siRNA)
|
Others
|
CPT1B Human Pre-designed siRNA Set A contains three designed siRNAs for CPT1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
CPT1B Human Pre-designed siRNA Set A
CPT1B Human Pre-designed siRNA Set A
-
- HY-RS03124
-
|
Small Interfering RNA (siRNA)
|
Others
|
CPT1C Human Pre-designed siRNA Set A contains three designed siRNAs for CPT1C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
CPT1C Human Pre-designed siRNA Set A
CPT1C Human Pre-designed siRNA Set A
-
- HY-16560S
-
Campathecin-d5; (S)-(+)-Camptothecin-d5; CPT-d5
|
Topoisomerase
ADC Cytotoxin
MicroRNA
Influenza Virus
Apoptosis
Fungal
Antibiotic
|
Infection
Cancer
|
Camptothecin-d5 is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].
|
-
-
- HY-16562A
-
(+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413
|
Topoisomerase
Autophagy
|
Cancer
|
Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
|
-
-
- HY-16568
-
(+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate
|
Topoisomerase
Autophagy
|
Cancer
|
Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
|
-
-
- HY-16562
-
(+)-Irinotecan; CPT-11; VAL-413(free base)
|
Topoisomerase
Autophagy
|
Cancer
|
Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
|
-
-
- HY-16562S
-
(+)-Irinotecan-d10; CPT-11-d10; VAL-413-d10
|
Topoisomerase
Autophagy
|
Cancer
|
Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].
|
-
-
- HY-161095
-
|
Others
|
Cancer
|
iRGD-CPT is a conjugate of iRGD and camptothecin
that is covalently coupled through a heterobifunctional linker. iRGD-CPT has
anticancer activity in vitroandin vivo.
iRGD-CPT can be used for the study of colon cancer .
|
-
-
- HY-111673
-
8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium
|
PKA
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC50 of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC50CPT-Cyclic AMP sodium is a very high affinity for Epac and is a potent Epac activator .
|
-
-
- HY-107543
-
|
Ras
|
Others
|
8-CPT-2Me-cAMP sodium is a selective activator of exchange proteins activated by cAMP (Epac), the cAMP sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50> 10 μM) . 8-CPT-2Me-cAMP sodium stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro .
|
-
-
- HY-112051
-
-
-
- HY-112667
-
-
-
- HY-120994
-
|
PKA
|
Neurological Disease
Inflammation/Immunology
|
Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
|
-
-
- HY-120994A
-
|
PKA
|
Neurological Disease
Inflammation/Immunology
|
Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
|
-
-
- HY-120994B
-
|
PKA
|
Neurological Disease
Inflammation/Immunology
|
Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .
|
-
-
- HY-108471
-
|
Toll-like Receptor (TLR)
|
Cancer
|
CU-CPT22 is a potent protein complex of toll-like receptor 1 and 2 (TLR1/2) inhibitor, and competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with a Ki of 0.41 µM. CU-CPT22 blocks Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 µM .
|
-
-
- HY-101929
-
-
-
- HY-112050
-
-
-
- HY-108473
-
TLR3-IN-1
|
Toll-like Receptor (TLR)
|
Cancer
|
CU-CPT 4a (TLR3-IN-1) is a potent, highly selective TLR3 signaling inhibitor. CU-CPT 4a represses the expression of downstream signaling pathways mediated by the TLR3/dsRNA complex, including TNF-α and IL-1β .
|
-
-
- HY-100309
-
9-Amino-20(S)-camptothecin; 9-Amino-CPT
|
Topoisomerase
|
Cancer
|
9-Aminocamptothecin (9-Amino-CPT) is a topoisomerase I inhibitor with potent anticancer activity .
|
-
-
- HY-115899
-
-
-
- HY-141473
-
Malonyl coenzyme A tetralithium
|
Endogenous Metabolite
Mitochondrial Metabolism
|
Metabolic Disease
|
Malonyl CoA (Malonyl coenzyme A) tetralithium is a substrate for fatty acid biosynthesis and an inhibitor of fatty acid oxidation. Malonyl CoA tetralithium is also a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1 .
|
-
-
- HY-50202
-
Etomoxir
Maximum Cited Publications
63 Publications Verification
(R)-(+)-Etomoxir
|
Apoptosis
|
Metabolic Disease
Cancer
|
Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
|
-
-
- HY-50202A
-
(R)-(+)-Etomoxir sodium salt
|
Apoptosis
|
Metabolic Disease
Cancer
|
Etomoxir((R)-(+)-Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig .
|
-
-
- HY-U00159
-
-
-
- HY-100620
-
APC
|
Topoisomerase
Cholinesterase (ChE)
|
Cancer
|
RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE .
|
-
-
- HY-149291
-
|
ATM/ATR
Apoptosis
|
Cancer
|
A011 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC50 value of 1.0 nM. A011 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). A011 combines with CPT-11 shows antitumor activity .
|
-
-
- HY-100638
-
NPC
|
|
|
RPR132595A (NPC) is an active metabolite of CPT-11, which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine .
|
-
-
- HY-100638A
-
NPC hydrochloride
|
Drug Metabolite
|
Cancer
|
RPR132595A (NPC) hydrochloride is an active metabolite of CPT-11, which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine .
|
-
-
- HY-B1334AS
-
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Cancer
|
Perhexiline-d11 (maleate) is the deuterium labeled Perhexiline maleate. Perhexiline maleate is a potent carnitine palmitoyltransferase 1 (CPT 1) inhibitor with IC50s of 77 and 148 μM for rat heart and liver CPT 1, respectively.
|
-
-
- HY-145513
-
|
Topoisomerase
|
Cancer
|
CL2-MMT-SN38 is a SN-38 derivative. SN-38, an anticancer agent, is an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11) .
|
-
-
- HY-161027
-
|
Apoptosis
|
Cancer
|
DHP-B possesses anti-cancer activity and induces apoptosis. DHP-B covalently binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 interaction, leading to increased mitochondrial permeability and reduced oxygen consumption and energy metabolism in CRC cells. DHP-B can be isolated from the plant Peperomia dindygulensis .
|
-
-
- HY-W104819
-
4-Hydroxyphenylglyoxylic acid; 4-HPGA
|
Others
|
Metabolic Disease
|
4-Hydroxyphenylglyoxylate (4-Hydroxyphenylglyoxylic acid) is an inhibitor of carnitine palmitoyltransferase I (CPT I). 4-Hydroxyphenylglyoxylate can be used to study sensitivity changes in CPT I of liver mitochondria and fatty acid oxidation by isolated hepatocytes. 4-Hydroxyphenylglyoxylate can inhibits fatty acid oxidation .
|
-
-
- HY-B1334A
-
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
|
-
-
- HY-B1334
-
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina .
|
-
-
- HY-156756
-
|
ADC Cytotoxin
|
Others
|
7-Hydroxymethyl-10,11-MDCPT is a payload that can be used for ADC synthesis .
|
-
-
- HY-156756S
-
-
-
- HY-N0197
-
-
-
- HY-115938
-
|
Others
|
Metabolic Disease
|
BEC2 is an ester derivative of Baicalin, with good lipid-lowering activity. BEC2 can direct activate the carnitine palmitoyltransferase 1A (CPT1A) .
|
-
-
- HY-N2063
-
|
Topoisomerase
|
Others
|
12-Ethyl-9-hydroxycamptothecin is a derivative of Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM .
|
-
-
- HY-12364
-
|
Fatty Acid Synthase (FASN)
|
Cancer
|
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
|
-
-
- HY-N2108
-
|
ADC Cytotoxin
|
Cancer
|
7-Ethylcamptothecin is one of camptothecin analogues. camptothecin (CPT), a cytotoxic alkaloid isolated from Camptotheca acuminata, is shown to have strong antitumor activity against L1210 leukemia and Walker 256 carcinosarcoma models .
|
-
-
- HY-136408
-
Malonyl coenzyme A lithium
|
Mitochondrial Metabolism
|
Metabolic Disease
|
Malonyl CoA (Malonyl Coenzyme A) lithium is an inhibitor of carnitine palmitoyl transferase 1 (CPT1). High Malonyl CoA lithium concentrations suppress fatty acid oxidation, while low Malonyl CoA lithium concentrations are permissive for fat oxidation .
|
-
- HY-130572
-
|
PROTAC Linkers
ADC Linker
|
Inflammation/Immunology
Cancer
|
Azido-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs, such as the conjugate CPT-APO (CPT: Camptothecin (HY-16560)). Azido-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG5-acid is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
- HY-12364B
-
|
Fatty Acid Synthase (FASN)
|
Cancer
|
(−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
|
-
- HY-114668
-
Camptothecin-20-O-propionate
|
Topoisomerase
|
Cancer
|
Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor .
|
-
- HY-114668A
-
Camptothecin-20-O-propionate hydrate
|
Topoisomerase
|
Cancer
|
Camptothecin-20(S)-O-propionate (Camptothecin-20-O-propionate) hydrate, the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate hydrate is a topoisomerase-Ι inhibitor .
|
-
- HY-146094
-
|
Topoisomerase
|
Cancer
|
Antitumor agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, is an antitumor agent without toxicity towards normal cells. Antitumor agent-63 shows high stability and very weak direct topoisomerase I (Topo I) inhibition .
|
-
- HY-N0446
-
|
ADC Cytotoxin
|
Cancer
|
10-Methoxycamptothecin is a natural bioactive derivative of camptothecin (CPT) isolated from Camptotheca acuminata, and has been confirmed to possess high anti-cancer properties. 10-Methoxycamptothecin has higher cytotoxicity than 10-hydroxycamptothecin by testing antitumor activity against 2774 cell lines .
|
-
- HY-16482
-
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .
|
-
- HY-128979
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Deruxtecan analog 2 (example 9 P3) is a Deruxtecan (HY-13631E) analog. Deruxtecan analog 2 is a agent-linker conjugate composed of Camptothecin (HY-16560) and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC .
|
-
- HY-143265
-
|
Topoisomerase
Apoptosis
Caspase
|
Cancer
|
Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-108433
-
Carnitine palmitoyltransferase 2
|
Biochemical Assay Reagents
|
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-16560S
-
|
Camptothecin-d5 is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].
|
-
-
- HY-156756S
-
|
7-Hydroxymethyl-10,11-MDCPT-d5 is deuterium labeled 7-Hydroxymethyl-10,11-MDCPT, which is a is a payload that can be used for ADC synthesis .
|
-
-
- HY-16562S
-
|
Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].
|
-
-
- HY-B1334AS
-
|
Perhexiline-d11 (maleate) is the deuterium labeled Perhexiline maleate. Perhexiline maleate is a potent carnitine palmitoyltransferase 1 (CPT 1) inhibitor with IC50s of 77 and 148 μM for rat heart and liver CPT 1, respectively.
|
-
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P82970
-
CPT1; CPT2; IIAE4; CPTASE
|
WB, IHC-P, ICC/IF
|
Human, Mouse, Rat |
-
- HY-P81167
-
CPT 1; CPT1A; CPTI-L; CPT1-L; carnitine palmitoyl transferase 1; Carnitine O-palmitoyltransferase 1, liver isoform; CPT I; Carnitine palmitoyltransferase 1A; carnitine O-palmitoyltransferase 1, liver isoform isoform 1; CPT1A_HUMAN.
|
WB; ELISA
|
Mouse(predicted: Human, Rat) |
CPT1A Antibody is an unconjugated, approximately 86 kDa, rabbit-derived, anti-CPT1A polyclonal antibody. CPT1A Antibody can be used for: WB, ELISA expriments in mouse, and predicted: human, rat background without labeling.
|
-
- HY-P80640
-
CPT7; CYP17; P450C17; S17AH; CYP17A1
|
WB
|
Human |
Cytochrome P450 17A1 Antibody (YA786) is a non-conjugated and Mouse origined monoclonal antibody about 57 kDa, targeting to Cytochrome P450 17A1 (6E1). It can be used for WB assays with tag free, in the background of Human.
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-130572
-
|
|
ADC Synthesis
PROTAC Synthesis
Azide
|
Azido-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs, such as the conjugate CPT-APO (CPT: Camptothecin (HY-16560)). Azido-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG5-acid is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: